These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 913230)

  • 21. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW; Bystritsky A
    J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose-response study in situational insomnia with zopiclone, a new tranquilizer.
    Giercksky KE; Wickstrom E
    Clin Ther; 1980; 3(1):21-7. PubMed ID: 6996815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
    Scharf MB; Roth T; Vogel GW; Walsh JK
    J Clin Psychiatry; 1994 May; 55(5):192-9. PubMed ID: 8071269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.
    Roger M; Attali P; Coquelin JP
    Clin Ther; 1993; 15(1):127-36. PubMed ID: 8458042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
    Xyrem International Study Group
    J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation.
    Chouinard G; Annable L; Steinberg S
    J Clin Psychopharmacol; 1986 Feb; 6(1):21-6. PubMed ID: 3512622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study.
    Ungvari GS
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):463-7. PubMed ID: 21220791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A standard- (trifluoperazine) controlled clinical study with clomacran in newly admitted schizophrenic patients.
    Pecknold JC; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1977 Jul; 13(3):14-5. PubMed ID: 329322
    [No Abstract]   [Full Text] [Related]  

  • 32. A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia.
    McEvoy JP; Berney S; Wilson WH; Ban TA; Guy W
    Int Pharmacopsychiatry; 1980; 15(5):318-24. PubMed ID: 7021452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced extrapyramidal signs in chronic liver disease--a case report.
    Park J; Logan R; Pottage A
    Clin Toxicol; 1977; 11(1):117-20. PubMed ID: 872535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled comparison of medium and high clorotepin doses in chronic schizophrenia.
    Bastecký J; Kalvach Z; Hálková E; Dusek K; Baborová E
    Act Nerv Super (Praha); 1979 Oct; 21(3):135-6. PubMed ID: 583192
    [No Abstract]   [Full Text] [Related]  

  • 35. Ambulatory activity during treatment with fluspirilene in chronic schizophrenics.
    Perris C; Rapp W
    Acta Psychiatr Scand Suppl; 1974; 249():117-22. PubMed ID: 4608470
    [No Abstract]   [Full Text] [Related]  

  • 36. Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.
    Clark ML; Costiloe JP; Wood F; Paredes A; Fulkerson FG
    Dis Nerv Syst; 1977 Nov; 38(11):943-7. PubMed ID: 913230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.
    Nestoros JN; Lehmann HE; Ban TA
    Int Pharmacopsychiatry; 1978; 13(3):138-50. PubMed ID: 355181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of butaclamol in chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    J Clin Pharmacol; 1977; 17(8-9):529-36. PubMed ID: 19510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of two dose levels of loxapine succinate in chronic schizophrenia.
    Clark ML; Paredes A; Costiloe JP; Fulkerson FG; Wood F
    Dis Nerv Syst; 1977 Jan; 38(1):7-10. PubMed ID: 318984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.